Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 3.28% | 334.84 | 0.0% | $4823.21m | |
| BNTX | BioNTech SE | 5.41% | 261.09 | 0.0% | $769.86m | |
| NVAX | Novavax, Inc. | 2.66% | 166.25 | 79.4% | $734.23m | |
| AMGN | Amgen, Inc. | -2.27% | 203.13 | 1.4% | $562.61m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -3.25% | 6.26 | 0.7% | $437.60m | |
| GILD | Gilead Sciences, Inc. | -2.56% | 65.90 | 1.0% | $415.54m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.76% | 543.48 | 2.7% | $401.78m | |
| ILMN | Illumina, Inc. | 0.15% | 410.53 | 3.3% | $393.44m | |
| CCXI | ChemoCentryx, Inc. | -5.92% | 32.43 | 2.9% | $364.70m | |
| XLRN | Acceleron Pharma, Inc. | 0.04% | 173.00 | 5.3% | $345.57m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.53% | 180.80 | 1.9% | $258.21m | |
| BIIB | Biogen, Inc. | -4.08% | 269.73 | 1.7% | $233.47m | |
| OCGN | Ocugen, Inc. | -4.62% | 8.26 | 0.0% | $170.13m | |
| XENE | Xenon Pharmaceuticals, Inc. | -8.73% | 30.72 | 0.4% | $162.62m | |
| CRSP | CRISPR Therapeutics AG | -0.81% | 96.21 | 0.6% | $151.63m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.